U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Frequently Asked Questions – Statement of Investigator (Form FDA 1572)
  1. Regulatory Information

INFORMATION SHEET

Frequently Asked Questions – Statement of Investigator (Form FDA 1572) Guidance for Sponsors, Clinical Investigators, and IRBs May 2010

Final

Frequently Asked Questions – Statement of Investigator (Form FDA 1572)

Issued by:
Guidance Issuing Office
Office of Good Clinical Practice
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research

This guidance is intended to assist sponsors, clinical investigators, and institutional review boards (IRBs) involved in clinical investigations of investigational drugs and biologics.  This guidance applies to clinical investigations conducted under 21 CFR Part 312 (Investigational New Drug Applications or IND regulations).  It describes how to complete the Statement of Investigator form (Form FDA 1572). 

The Food and Drug Administration (FDA or agency) has received a number of questions about Form FDA 1572.  The most frequently asked questions are answered below.  If you do not see your question answered here, you may submit it to gcp.questions@fda.hhs.gov or druginfo@fda.hhs.gov


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.